fCAL® turbo RECEIVES 510(K) CLEARANCE IN THE USA | Gentian
medical, diagnostics, immunoassays, assays, in vitro diagnostics, IVD products, avian antibodies, antibodies, clinical chemistry, diagnostic tests, biotechnology
19282
post-template-default,single,single-post,postid-19282,single-format-standard,ajax_fade,page_not_loaded,,qode-content-sidebar-responsive,qode-child-theme-ver-1.0.0,qode-theme-ver-14.2,qode-theme-bridge,wpb-js-composer js-comp-ver-6.0.5,vc_responsive
 

fCAL® turbo RECEIVES 510(K) CLEARANCE IN THE USA

fCAL® turbo RECEIVES 510(K) CLEARANCE IN THE USA

Moss, 28.06.2019

 

Gentian Diagnostics AS is pleased to announce that BÜHLMANN has received 510(k) clearance (K190784) from the FDA for the BÜHLMANN fCAL® turbo. BÜHLMANN is Gentian’s exclusive commercial partner for the fecal calprotectin products worldwide.

 

The potential US fecal calprotectin market is of an estimated size of USD ~30 million, while the current market is of an estimated size of USD ~5 million. Hilja Ibert, CEO Gentian Diagnostics AS comments “While the fecal calprotectin market size in the US is still quite small, fecal calprotectin is part of a high annual growth market, as observed in Europe. The already FDA cleared BÜHLMANN fCAL® ELISA has paved the way for BÜHLMANN fCAL® turbo which will allow for high throughput analysis of fecal calprotectin in applicable core laboratories and screening programmes.”

 

For further information, please contact:
Hilja Ibert CEO
Gentian Diagnostics AS
E-mail: hilja.ibert@gentian.no
Cell Phone: +47 919 05 242

 

Njaal Kind CFO,
Gentian Diagnostics AS
E-mail: njaal.kind@gentian.no
Cell Phone: +47 919 06 525
MeldingsID: 480471